What's in Instituto Grifols, S.A.'s pipeline?

Instituto Grifols, S.A. has 6 drugs in our index: 4 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Instituto Grifols, S.A.'s portfolio?

Top competitors by shared drug class: ADMA Biologics, Inc., Baxalta now part of Shire, Bio Products Laboratory, Biotest, CSL Behring.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/instituto-grifols-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Instituto Grifols, S.A. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Instituto Grifols, S.A. pipeline: 4 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Human thrombin	Human thrombin	marketed
Flebogamma 5% DIF	Flebogamma 5% DIF	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors, pathogenic antigens and antibodies	Immunology
Prolastin	Prolastin	marketed			Other
Bovine thrombin	Bovine thrombin	marketed	Coagulation factor / Hemostatic agent	Fibrinogen	Hematology / Hemostasis
IGIV3I Grifols	IGIV3I Grifols	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens	Immunology
Fibrin Sealant Grifols	Fibrin Sealant Grifols	phase 3	Fibrin sealant / Hemostatic agent	Fibrinogen (substrate for thrombin-catalyzed polymerization)	Surgery / Hemostasis

Therapeutic area mix

Immunology · 2
Hematology / Hemostasis · 1
Other · 1
Surgery / Hemostasis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ADMA Biologics, Inc. · 1 shared drug class
Baxalta now part of Shire · 1 shared drug class
Bio Products Laboratory · 1 shared drug class
Biotest · 1 shared drug class
CSL Behring · 1 shared drug class
CSL Limited · 1 shared drug class
Ethicon, Inc. · 1 shared drug class
Grifols Biologicals, LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Instituto Grifols, S.A.:

Cite this brief

Drug Landscape (2026). Instituto Grifols, S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-grifols-s-a. Accessed 2026-05-17.